A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Biomarker; Pharmacodynamics
- 04 Jun 2024 Results investigating the association of RNA sequencing (RNAseq)-based gene expression signatures (GES) at baseline and on-treatment (C1D15), with early metabolic change on PET/CT and clinical outcomes, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 14 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 May 2025.
- 23 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.